

# CT26 TTPKO cell line

**Catalogue number:** 157876

**Sub-type:** Continuous

**Images:**

## Contributor

**Inventor:** Julian Downward

**Institute:** The Francis Crick Institute

**Images:**

## Tool details

**\*FOR RESEARCH USE ONLY**

**Name:** CT26 TTPKO cell line

**Alternate name:** TTP

**Class:**

**Conjugate:**

**Description:** CRISPR/Cas tristetraprolin (TTP) Knock-out KRAS mutant colon carcinoma cell line. In some immunoresistant tumours, PD-L1 expression is upregulated by RAS activation. Via the MEK pathway, the MK2 kinase phosphorylates and inhibits TTP, which negatively regulates PD-L1 expression. PD-L1 is a therapeutic target to check the immune evasion mechanism of some cancers. CRISPR edited CT26 cells.

**Purpose:**

**Parental cell:** CT26 ATCC-CRL-2638

**Organism:** Mouse

**Tissue:**

**Model:** Knock-Out

**Gender:**

**Isotype:**

**Reactivity:**

**Selectivity:**

**Host:**

**Immunogen:**

**Immunogen UNIPROT ID:**

**Sequence:**

**Growth properties:**

**Production details:** CRISPR/Cas TTP Knock-out KRAS mutant colon carcinoma cell line. Knock Out of functional TTP was confirmed by Western blot. Complete Zfp36 allele disruption was confirmed by

TOPO-TA cloning followed by sequencing. Mouse Zfp36 was targeted with gRNA sequence GTCATGGCTCATCGACTGGAGG, using U6gRNA-Cas9-2A-GFP

**Formulation:**

**Recommended controls:** CT26 ATCC-CRL-2638 parental cells

**Bacterial resistance:**

**Selectable markers:**

**Additional notes:** CRISPR edited CT26 cells. Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here. This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide...

## Target details

**Target:** Tristetraprolin (TTP)

**Target alternate names:**

**Target background:**

**Molecular weight:**

**IC50:**

## Applications

**Application:**

**Application notes:** Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here: [https://www.cancertools.org/tool-faqs#hs\\_cos\\_wrapper\\_widget\\_1649861453796](https://www.cancertools.org/tool-faqs#hs_cos_wrapper_widget_1649861453796) This license from ERS Genomics Ltd allows CancerTools.org to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. CancerTools.org can provide these modified CRISPR-Cas9 cell lines to comp...

## Handling

**Format:** Frozen

**Concentration:**

**Passage number:**

**Growth medium:** RPMI-1640 + 10% FCS. Subculture split ratio of 1:4 to 1:10 every 2-3 days.

**Temperature:**

**Atmosphere:**

**Volume:**

**Storage medium:**

**Storage buffer:**

**Storage conditions:**

Liquid Nitrogen

**Shipping conditions:** Dry ice

## Related tools

**Related tools:**

## References

**References:** Jesus et al. 2015. Virology. 481:1-12. PMID: 25765002.

CancerTools.org